Data Demonstrating Aeolus Pharmaceuticals Inc.' AEOL 10150's Efficacy as a Broad Spectrum Pharmaceuticals, Inc. Countermeasure Against Radiological and Chemical Threats Presented at the GHSI Public Health Emergency Medical Countermeasures Workshop

MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today the presentation of data at the GHSI Public Health Emergency Medical Countermeasures Workshop detailing the potential of AEOL 10150 as a broad spectrum medical countermeasure (MCM) to treat radiological and chemical threats. Data presented from studies sponsored by Aeolus, the National Institutes of Health (NIH), National Institutes of Allergies and Immunological Disorders and NIH CounterACT, highlighted AEOL 10150’s efficacy in animal models of Acute Radiation Syndrome (ARS), sulfur mustard gas and chlorine gas exposure.